Abstract:Chemical biology is a scientific interdiscipline spanning the fields of chemistry and biology that involves the application of chemical tools, often compounds, to the study and manipulation of biological systems. Remarkable achievements have been obtained on chemical biology which aims to study important biological events by using small molecular active compounds as a probe thus small active compound has become effective tools in the research of biomedicine. Our research group has achieved a series of results in the molecular mechanism study of leukemic cell differentiation and apoptosis through using small molecular active compounds. We discovered that adenanthin, a diterpenoid compound extracted from Rabdosia adenantha, induces APL-like cell differentiation, represses tumor growth in vivo and prolongs the survival of mouse APL models that are sensitive and resistant to retinoic acid. The chemical probe biotin-tagged adenanthin was designed on the basis of structure-activity relationship data. Further study demonstrated adenanthin directly targets the conserved resolving cysteines of PrxI and Prx II and inhibits their peroxidase activities. Consequently, cellular H 2O 2 is elevated, leading to the activation of extracellular signal regulated kinases and increased transcription of C/EBPβ, which contributes to adenanthin-induced differentiation. In another study we identified a novel natural ent-kaurene diterpenoid derived from I. pharicus leaves called pharicin B that can rapidly stabilize RARα as well as PML-RARα protein and enhances ATRA-dependent transcriptional activity of RARα. Additionally, pharicin B enhances differentiation-enhancing effect of ATRA in AML cell lines, some primary leukemic cells and overcomes retinoid resistance in ATRA-resistant subclones. The effectiveness of the ATRA/pharicin B combination warrants further investigation on their use as a therapeutic strategy for AML patients.Based on our previous study that NSC606985, a novel camptothecin analog, could effectively induce apoptosis in AML cells in a time- and concentration-dependent manner, sequentially through proteolytic activation of protein kinase Cδ (PKCδ), loss of mitochondrial Δωm and caspase-3 activation, we further employed NSC606985 as a molecule probe and systemically investigated the mechanisms of apoptotic induction in AML cells and the prospects of its clinical application in vitro and in vivo. We analyzed protein expression profiles of NSC606985-induced apoptotic AML cells by systematically using phosphoproteomics, quantitive proteomics as well as subcellular proteomics analytical strategy. As a result, we uncovered a series of deregulated proteins including translocated ones during apoptosis, most of which had not been reported previously. Among these apoptotic proteins we identified, the function of ANP32B as well as NDRG1 and their relationship with NSC606985-triggered AML cell apoptosis were further investigated respectively. Moreover, the in vivo study demonstrated that NSC606985 rapidly induced apoptosis of leukemic cells in peripheral blood, bone marrow, liver and spleen, and administration of NSC606985 significantly prolonged the survival of AML mice. The above results provide new leading compound for the acute leukemia therapy. The study of "New Mechanism for Differentiation and Apoptosis of Leukemic cell" wins the National Awards of Natural Sciences (Second prize) in 2010.

Identification of Chlorprothixene As a Potential Drug That Induces Apoptosis and Autophagic Cell Death in Acute Myeloid Leukemia Cells.

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Genistein Induces Apoptosis in Acute Myeloid Leukemia Cells and Affects Proteasome Pathway by Proteomic Analysis

CXCR4-mediated Signaling Regulates Autophagy and Influences Acute Myeloid Leukemia Cell Survival and Drug Resistance.

Targeting CaMKII-δ/DHCR24 Axis is a Novel Strategy Against Acute Myeloid Leukemia

Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns

Exploring Prognostic Biomarkers of Acute Myeloid Leukemia to Determine Its Most Effective Drugs from the FDA-Approved List through Molecular Docking and Dynamic Simulation

Chemical biology study for differentiation and apoptosis of leukemic cell

Demethylation Strategies for the Treatment of Acute Myeloid Leukemia: Targeting Protacs That Degrade DNA Methyltransferase

Abstract 2532: Deciphering multiple protein complexes in BCL2 family to measure apoptotic dependencies in acute myeloid leukemia

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia

Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway

Identification of JL1037 As a Novel, Specific, Reversible Lysine-Specific Demethylase 1 Inhibitor That Induce Apoptosis and Autophagy of AML Cells.

Pyridoxine induces monocyte-macrophages death as specific treatment of acute myeloid leukemia

The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia

Autophagy inhibition induces AML cell death and enhances the efficacy of chemotherapy under hypoxia

Targeting PI3K, Mtor, ERK, and Bcl-2 Signaling Network Shows Superior Antileukemic Activity Against AML

Identifying a prognostic model and screening of potential natural compounds for acute myeloid leukemia

Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway

The Identification of APOBEC3G as a Potential Prognostic Biomarker in Acute Myeloid Leukemia and a Possible Drug Target for Crotonoside